Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Renal parenchymal blood flow can be divided in cortical and medullary blood flow. Changes and factors affecting renal medullary blood flow have not been studied in detail previously as investigators/doctors did not have tools to monitor renal medullary blood flow in vivo. Since Trueta first described renal medullary blood flow, multiple attempts have been made to study renal medullary blood flow using invasive methods. Recently renal medullary blood flow measurement using contrast US has emerged as a promising technique that investigators can use to study renal medullary blood flow in vivo. In this study investigators are aiming to study changes in renal parenchymal (cortical and medullary) blood flow with exercise in healthy subject.
This study requires a screening day and two visits on separate days to the Clinical Research Unit (CRU). Three visits total.
Screening Visit:
Study Day #1 The subjects will arrive in the CRU in the morning. Subjects' understanding of all study related procedures will be assessed and all remaining questions will be answered. The following sequence of procedures will be followed for all enrolled subjects.
Physical exam including vital signs (Blood Pressure, Heart Rate, Weight, Height, Respiration Rate, Temperature)
Urine pregnancy test for women of child bearing age. If positive, subjects will be excluded.
Determination of peak oxygen consumption
Subjects will complete a continuous VO2 peak bicycle ergometer protocol.
On Day 2 of testing
Check Vitals (BP, HR, Wt., RR, Temp.)
Insert peripheral IV line Baseline renal blood flow measurement using contrast enhanced ultrasonography
The Definity vial will be placed at room temperature before being used. It will be activated after shaking the vial using Vialmax® for 45 seconds. It will be used immediately after activation.
0.4 ml of Definity will be mixed in 10 ml of preservative free saline.
Infusion of Definity into a peripheral vein will be started at 2 ml/min and titrated for optimal image quality using a minipump (not to exceed 10 ml/min at any time).
Baseline contrast ultrasound imaging of right kidney will be performed with low mechanical index (MI) of 0.2.
4 - 5 ultrasound impulses with high MI of 1.0 and duration of 1 second will be used to destruct the microbubbles in the kidney tissue
Ultrasound imaging of the kidney with low MI (0.2) will continue immediately after each impulse for several seconds.
Infusion of Definity will stop at this point.
Vital signs will be monitored every 15 minutes and continuous pulse oximetry will be performed during Definity administration.
Vital signs and pulse oximetry will be monitored every 15 minutes until 30 minutes after discontinuation of Definity.
A urine dipstick will be performed by the study team 30 minutes after completion of Definity infusion if a sample is available.
Constant load Exercise protocol
Subjects will complete 30 minutes of continuous cycling at the power output associated with 85% of VO2peak from the continuous bicycle ergometer protocol. Metabolic data will be collected as described above.
Once metabolic parameter are reached, exercise will be stopped and subject will be asked to lie down on the bed Renal Blood flow measurement following exercise using contrast enhanced ultrasonography
Immediately after completion of exercise protocol, steps 5 - 12 under day 2 procedures will be repeated.
The study procedures will end at this point.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Test Subjects | Experimental | We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Definity | Drug | During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in renal blood flow in exercise as assessed by CEUS | Total, cortical and medullary kidney blood flow will be measured using contrast-enhanced ultrasonography | Before and immediately after exercise |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sharon F Johnson, BA | Contact | 4349823198 | sfj8n@virginia.edu | |
| Kambiz Kalantarinia, MD | Contact | 434982-3198 | KK6C@hscmail.mcc.virginia.edu |
| Name | Affiliation | Role |
|---|---|---|
| Kambiz Kalantarinia, MD | University of Virginia, Department of Nephrology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Virginia | Recruiting | Charlottesville | Virginia | 22908 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 7, 2022 | |
| Reset | Mar 31, 2022 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Exercise | Other |
|
|
| Kidney Ultrasound | Other | This done before and after exercise with the help of Definity to see changes in kidney blood flow |
|
|
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 7, 2022 | Mar 31, 2022 |
| ID | Term |
|---|---|
| C042852 | perflutren |
| D045423 | Microbubbles |
| D015444 | Exercise |
| ID | Term |
|---|---|
| D004864 | Equipment and Supplies |
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided